CN115475132A - 可改善肌肤痘印的护肤品组合物及制备方法 - Google Patents
可改善肌肤痘印的护肤品组合物及制备方法 Download PDFInfo
- Publication number
- CN115475132A CN115475132A CN202210780911.5A CN202210780911A CN115475132A CN 115475132 A CN115475132 A CN 115475132A CN 202210780911 A CN202210780911 A CN 202210780911A CN 115475132 A CN115475132 A CN 115475132A
- Authority
- CN
- China
- Prior art keywords
- acne
- skin
- composition
- lightening
- soothing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 66
- 206010000496 acne Diseases 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002537 cosmetic Substances 0.000 claims abstract description 24
- 206010061218 Inflammation Diseases 0.000 claims abstract description 7
- 230000004054 inflammatory process Effects 0.000 claims abstract description 7
- 238000005562 fading Methods 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 23
- 244000146462 Centella asiatica Species 0.000 claims description 16
- 235000004032 Centella asiatica Nutrition 0.000 claims description 16
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 12
- 241001172538 Daemonorops draco Species 0.000 claims description 11
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 10
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 10
- 229940106189 ceramide Drugs 0.000 claims description 10
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 10
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 10
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 6
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 6
- 229960000458 allantoin Drugs 0.000 claims description 6
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims description 6
- 229940101267 panthenol Drugs 0.000 claims description 6
- 235000020957 pantothenol Nutrition 0.000 claims description 6
- 239000011619 pantothenol Substances 0.000 claims description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims description 3
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 claims description 3
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims description 3
- 229940022757 asiaticoside Drugs 0.000 claims description 3
- 229940090813 madecassoside Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 238000000194 supercritical-fluid extraction Methods 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 208000020154 Acnes Diseases 0.000 abstract description 7
- 239000000686 essence Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 6
- FBNAWLJSQORPAX-UHFFFAOYSA-N 4-methyl-3-propan-2-ylphenol Chemical compound CC(C)C1=CC(O)=CC=C1C FBNAWLJSQORPAX-UHFFFAOYSA-N 0.000 description 5
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000221696 Sclerotinia sclerotiorum Species 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000009286 sanguis draxonis Substances 0.000 description 2
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical group CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- 241001530056 Athelia rolfsii Species 0.000 description 1
- 241001313857 Bletilla striata Species 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 241000292342 Dracaena cochinchinensis Species 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- 241001428166 Eucheuma Species 0.000 description 1
- 229910001374 Invar Inorganic materials 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000001180 angelica archangelica l. root extract Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940084801 salvia miltiorrhiza root extract Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
本发明属于化妆品技术领域,具体公开了一种改善肌肤痘印的组合物,其包含百分之零点一至百分之十的o‑伞花烃‑5‑醇和丙二醇的混合物(丙二醇与o‑伞花烃‑5‑醇的质量配比为9:1)、百分之零点零五至百分之五的积雪草提取物、百分之零点零五至百分之二十的麒麟竭提取物、百分之零点一至百分之五的复合神经酰胺、百分之零点一至百分之五的泛醇、百分之零点零一至百分之一透明质酸钠、百分之零点零一至百分之零点五的尿囊素。本发明的组合物具效抗炎舒缓、祛痘及修护痘后肌肤和淡化痘印的作用。
Description
技术领域
本发明涉及到日用化妆品领域,尤其涉及一种有效抗炎舒缓、祛痘及修护痘后肌肤和淡化痘印的组合物及制备方法。
背景技术
化妆品已是生活必需品,有着清洁美化肌肤的作用。随着科学的发展和时代的进步,人们对化妆品的功效要求越来越高,相关监管部门也在对化妆品功效宣称的有效性进行规范监管;随着生活环境的变化,生活节奏的加快,皮肤出现痘痘问题的人群越来越多;痘是痤疮的俗称,是发生于毛囊皮脂腺的一种慢性炎症。
目前市场上存在多种祛痘的化妆品,主要是通过消炎杀菌、控制油脂分泌等途径达到祛痘护痘印的目的,但是存在着对刺激性大、效果不明显、容易复发等缺点;也有用植物提取物组合,存在使用时间长、效果不明显等缺点。中国发明专利申请公开号为CN108186679A的中国专利公开了一种祛痘组合物,包含富勒烯、尿囊素和油脂类等物质;该发明宣称具有治疗痘痘和修护痘痕的问题,具体的原因没有阐述清楚;中国发明专利申请公开号为 CN111743831A的中国专利公开了一种祛痘组合物,包括番石榴果提取物、黄檗提取物、丹参根提取物、黄芩根提取物、当归根提取物等,存在作用机理不明确,祛痘功效证明不明显,缺乏对祛痘后肌肤的修护等问题。
发明内容
本发明的目的是,克服现有的祛痘化妆品的缺陷,提供一种新的抗炎舒缓、祛痘及修护痘后肌肤受损和淡化痘印的组合物。
本发明的目的及解决的技术问题是通过以下技术方案来实现的。依据本发明提出的抗炎舒缓、祛痘及修护痘后肌肤受损和淡化痘印的组合物,所述组合物包含o-伞花烃-5-醇和或积雪草(CENTELLA ASIATICA)提取物和或羟基积雪草甙和或积雪草苷和或麒麟竭(DAEMONOROPS DRACO)提取物和或复合神经酰胺和或泛醇和或透明质酸钠。
本发明的化妆品组合物,包含所述o-伞花烃-5-醇,其化学名称为异丙基甲基苯酚,使用时与丙二醇混合使用,此混合物(丙二醇与o-伞花烃-5-醇的配比为9:1)优选包含0.1%至10%,更优选为0.1-1%。
本发明的化妆品组合物,包含所述的积雪草(CENTELLA ASIATICA)提取物,积雪草苷含量大概为15%,羟基积雪草甙含量大概为55%;本发明中积雪草(CENTELLA ASIATICA)提取物用量在0.05-5%,更优选为0.1-2%。
本发明的化妆品组合物,包含所述的麒麟竭(DAEMONOROPS DRACO)提取物,麒麟竭为百合科剑叶龙血树的树脂,主要分布在我国云南及东南亚地区。树皮被割破,便会流出殷红的汁液,主要成分为龙血素B,具有的抗炎镇痛、活血散瘀的功效。采用二氧化碳超临界萃取技术,保护了活性成分不被破坏及提取物的纯净。本发明中麒麟竭(DAEMONOROPS DRACO)提取物用量在0.05-20%,更优选为0.5-10%。
本发明的化妆品组合物,包含所述的复合神经酰胺,其商品名为SK-influx(厂家为赢创特种化学(上海)有限公司),由神经酰胺6II、或神经酰胺3、植物鞘氨醇和或胆甾醇组成。
一种可改善肌肤痘印的护肤品组合物,包含如下质量分数的各组分:如图1所示
表1
附图说明
图1一种可改善肌肤痘印的护肤品组合物包含各组分及质量分数
图2本发明实施例的1-2的化妆品组合物制成的精华液成分
图3测试者使用按实施例2配制成精华液第0天和第21天的VISIA拍摄图
图4实施例1-2使用精华液可改善皮肤痘印效果的观察及测试者自评价
图5使用空白及实施例1-2后刺激性的观察结果
附图是一种可改善肌肤痘印的护肤品组合物包含各组分及质量分数图,即说明书附图中图1一种可改善肌肤痘印的护肤品组合物包含各组分及质量分数;附图是本发明实施例的 1-2的化妆品组合物制成的精华液成分图,即说明书附图中图2本发明实施例的1-2的化妆品组合物制成的精华液成分;附图是测试者使用按实施例2配制成精华液第0天和第21天的 VISIA拍摄图,即说明书附图中图3测试者使用按实施例2配制成精华液第0天和第21天的 VISIA拍摄图;附图是实施例1-2使用精华液可改善皮肤痘印效果的观察及测试者自评价图,即说明书附图中图4实施例1-2使用精华液可改善皮肤痘印效果的观察及测试者自评价;附图是使用空白及实施例1-2后刺激性的观察结果,即说明书附图中图5使用空白及实施例1-2 后刺激性的观察结果。
具体实施方式
本发明公开了一种改善肌肤痘印的护肤品组合物,其包含0.01-0.1%o-伞花烃-5-醇,和或0.05-5%积雪草(CENTELLA ASIATICA)提取物,和或0.05-20%麒麟竭(DAEMONOROPS DRACO) 提取物,和或0.1-5%复合神经酰胺,和或0.1-5%泛醇,和或0.01-1%透明质酸钠,和或0.01-0.5%尿囊素。
本发明化妆品组合物制成精华液的制备方法,可表述如下:
制备方法:将尿囊素、透明质酸钠、甜菜碱、甘油、卡波、小核菌胶加入到去离子水中,升温80℃下搅拌均匀,然后用三乙醇胺中和至pH为5.5-7.0,降温到40℃再加入o-伞花烃-5- 醇、积雪草(CENTELLA ASIATICA)提取物、复合神经酰胺、泛醇、麒麟竭(DAEMONOROPSDRACO) 提取物,搅拌均匀,最后加入香精和防腐剂。
表2显示的是本发明实施例的1-2的化妆品组合物制成的精华液(如图2所示)
序号 | 成分 | 空白 | 实施例1 | 实施例2 |
1 | 去离子水 | 余量 | 余量 | 余量 |
2 | 卡波U20 | 0.2 | 0.2 | 0.2 |
3 | 透明质酸钠 | 0.05 | 0.05 | 0.05 |
4 | 对羟基苯甲酸甲酯 | 0.1 | 0.1 | 0.1 |
5 | 甜菜碱 | 1 | 1 | 1 |
6 | 尿囊素 | 0.1 | 0.1 | 0.1 |
7 | 甘油聚醚-26 | 2 | 2 | 2 |
8 | 小核菌胶 | 0.02 | 0.02 | 0.02 |
9 | 三乙醇胺 | 0.15 | 0.15 | 0.15 |
10 | o-伞花烃-5-醇 | - | 0.1 | 0.08 |
11 | 丙二醇 | 4 | 4 | 4 |
12 | SK-influx | - | 0.5 | 1 |
13 | 积雪草(CENTELLA ASIATICA)提取物 | - | 0.5 | 1 |
14 | 泛醇 | 1 | 1 | 1 |
15 | 麒麟竭(DAEMONOROPS DRACO)提取物 | - | 0.5 | 1 |
16 | 苯氧乙醇 | 0.25 | 0.25 | 0.25 |
17 | 己二醇 | 0.5 | 0.5 | 0.5 |
改善脸部肌肤痘印的功效测试结果:
为确认使用效果,选取30名年龄在21-30岁之间的志愿者(男性10人,女性20人)脸部有痘肌问题的测试者进行功效测试,采用VISIA专业皮肤分析仪*对面部患有明显红色痘印 (痤疮后红斑)的患者进行检测,形成空白对照数据。按实施例2配制成精华液,针对面部明显红色痘印(痤疮后红斑)的测试者,每日早晚涂精华液于脸部,使用21天后,通过VISIA专业皮肤分析仪(广州仪人分析仪器有限公司)进行检测,观察测试者使用前后面部红色痘印的泛红程度,来评估精华液改善寻常痤疮后红斑的效果及其安全性,如下图,某位测试者
使用第0天和第21天的VISIA拍摄图,看出使用实施例2的精华液21天后皮肤痘印有明显的改善。(如图3所示)
本发明化妆品组合物制成精华水的制备方法,可表述如下:
制备方法:将尿囊素、透明质酸钠、甜菜碱、甘油、卡波、小核菌胶加入到去离子水中,升温80℃下搅拌均匀,然后用三乙醇胺中和至pH为5.5-7.0,降温到40℃再加入o-伞花烃-5- 醇、积雪草(CENTELLA ASIATICA)提取物、复合神经酰胺、泛醇、麒麟竭(DAEMONOROPSDRACO) 提取物,搅拌均,最后加入香精和防腐剂。
表3为实施例1-2使用精华液可改善皮肤痘印效果的观察及测试者自评价(如图4所示)
表4为使用空白及实施例1-2后刺激性的观察结果(如图5所示)
从表3、表4中看出,使用本组合物的精华液具有明显改善皮肤痘印的效果,且使用中没有什么刺激性。
Claims (9)
1.一种可以有效抗炎舒缓、祛痘及修护痘后肌肤和淡化痘印的组合物,其特征在于:所述组合物包括以下重量百分含量的组分:o-伞花烃-5-醇和丙二醇的混合物(丙二醇与o-伞花烃-5-醇的质量配比为9:1)0.1-10% ,积雪草(CENTELLA ASIATICA)提取物0.05-5%,麒麟竭(DAEMONOROPS DRACO)提取物0.05-20%,复合神经酰胺(其商品名SK-influx)0.1-5%,泛醇0.1-5%,透明质酸钠0.01-1,尿囊素0.01-0.5%。
2.根据权利要求1所述的舒缓、祛痘及修护痘后肌肤和淡化痘印的化妆品组合物,其特征在于:所述o-伞花烃-5-醇,使用时是和丙二醇混合使用,按重量百分比,所述o-伞花烃-5-醇占组合物总量的0.1-1%。
3.根据权利要求1所述的舒缓、祛痘及修护痘后肌肤和淡化痘印的化妆品组合物,其特征在于:所述积雪草(CENTELLA ASIATICA)提取物,积雪草苷含量大概为15%,羟基积雪草甙含量大概为55%;按重量百分比,所述积雪草(CENTELLA ASIATICA)提取物占组合物总量的0.05-20%。
4.根据权利要求1所述的舒缓、祛痘及修护痘后肌肤和淡化痘印的化妆品组合物,其特征在于:所述麒麟竭(DAEMONOROPS DRACO)提取物,采用二氧化碳超临界萃取技术,保护了活性成分不被破坏及提取物的纯净;按重量百分比,所述麒麟竭(DAEMONOROPS DRACO)提取物占组合物总量的0.05-5%。
5.根据权利要求1所述的舒缓、祛痘及修护痘后肌肤和淡化痘印的化妆品组合物,其特征在于:所述复合神经酰胺,其商品名SK-influx,按重量百分比,所述复合神经酰胺占组合物总量的0.1-5%。
6.根据权利要求1所述的舒缓、祛痘及修护痘后肌肤和淡、化痘印的化妆品组合物,其特征在于:所述泛醇占组合物总量的0.1-5%。
7.根据权利要求1所述的舒缓、祛痘及修护痘后肌肤和淡化痘印的化妆品组合物,其特征在于:所述尿囊素占组合物总量的0.01-0.5%。
8.根据权利要求1所述的舒缓、祛痘及修护痘后肌肤和淡化痘印的化妆品组合物,其特征在于:所述透明质酸钠占组合物总量的0.01-0.5%。
9.权利要求1-8中任何一项所述的舒缓、祛痘及修护痘后肌肤和淡化痘印的化妆品组合物,其特征在于:还进一步包含:水溶性高分子、乳化剂、金属离子螯合剂、多元醇、pH调节剂、防腐剂、水、润肤油脂,氨基酸的一种或两种以上组合。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210780911.5A CN115475132A (zh) | 2022-07-05 | 2022-07-05 | 可改善肌肤痘印的护肤品组合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210780911.5A CN115475132A (zh) | 2022-07-05 | 2022-07-05 | 可改善肌肤痘印的护肤品组合物及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115475132A true CN115475132A (zh) | 2022-12-16 |
Family
ID=84422161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210780911.5A Pending CN115475132A (zh) | 2022-07-05 | 2022-07-05 | 可改善肌肤痘印的护肤品组合物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115475132A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107440987A (zh) * | 2017-08-15 | 2017-12-08 | 非果(上海)国际贸易有限公司 | 一种调解面部微循环的化妆品及其制备工艺 |
CN109806194A (zh) * | 2017-11-22 | 2019-05-28 | 广州慕可生物科技有限公司 | 一种祛痘凝胶及其制备方法 |
CN110179737A (zh) * | 2019-05-30 | 2019-08-30 | 科索瑞生物科技(天津)有限公司 | 护肤液及其制备方法 |
CN111743830A (zh) * | 2020-06-19 | 2020-10-09 | 广州天玺生物科技有限公司 | 一种祛痘组合物及其应用 |
CN113368018A (zh) * | 2020-03-10 | 2021-09-10 | 盈妆生物科技(上海)有限公司 | 抗炎祛痘组合物及其制备方法 |
US20210290707A1 (en) * | 2018-02-28 | 2021-09-23 | Symrise Ag | Dermatological Product |
-
2022
- 2022-07-05 CN CN202210780911.5A patent/CN115475132A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107440987A (zh) * | 2017-08-15 | 2017-12-08 | 非果(上海)国际贸易有限公司 | 一种调解面部微循环的化妆品及其制备工艺 |
CN109806194A (zh) * | 2017-11-22 | 2019-05-28 | 广州慕可生物科技有限公司 | 一种祛痘凝胶及其制备方法 |
US20210290707A1 (en) * | 2018-02-28 | 2021-09-23 | Symrise Ag | Dermatological Product |
CN110179737A (zh) * | 2019-05-30 | 2019-08-30 | 科索瑞生物科技(天津)有限公司 | 护肤液及其制备方法 |
CN113368018A (zh) * | 2020-03-10 | 2021-09-10 | 盈妆生物科技(上海)有限公司 | 抗炎祛痘组合物及其制备方法 |
CN111743830A (zh) * | 2020-06-19 | 2020-10-09 | 广州天玺生物科技有限公司 | 一种祛痘组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108969446B (zh) | 一种增强皮肤屏障功能的婴幼儿防皴护肤组合物及其制备方法 | |
CN113143834B (zh) | 祛痘护肤组合物及其制备方法 | |
CN112494406A (zh) | 一种美白祛斑化妆品及其制备方法 | |
CN110075046B (zh) | 一种可袪痘淡痕的组合物 | |
CN110025513B (zh) | 一种含矿物温泉的无痕修复组合物 | |
CN113893209B (zh) | 一种祛痘修护功能组合物、其在化妆品中的应用和凝胶及制备方法 | |
CN113693979B (zh) | 一种控油祛痘组合物及其应用 | |
CN112569152B (zh) | 一种控油抗炎的植物组合提取物及其制备方法和应用 | |
WO2024045952A1 (zh) | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 | |
CN112076133A (zh) | 一种复方植物祛痘组合物及其制备方法和应用 | |
CN112426390A (zh) | 一种天然中药祛痘组合物及其制备方法 | |
CN112472642A (zh) | 一种可即时舒缓的化妆品组合物及其应用 | |
CN117653582B (zh) | 一种含有青蒿提取物的祛痘洗发组合物、制备与应用 | |
CN114588060A (zh) | 一种具有祛痘功效的美白保湿面膜及其制备方法 | |
CN116270367A (zh) | 一种净颜祛痘精华液及其制备方法 | |
CN112516066B (zh) | 一种控油组合物及其在化妆品中的应用 | |
CN114569531A (zh) | 一种清凉型面膜用修复基液及其制备方法 | |
CN113425661A (zh) | 一种具有清洁修护功效的植物组合物及其应用 | |
CN1357321A (zh) | 减少炎症和红斑的方法 | |
CN113318221A (zh) | 一种含羟基酪醇的有机混合酸祛痘液及其制备方法 | |
CN112402308A (zh) | 一种多效舒缓保湿水及其制备方法 | |
CN115475132A (zh) | 可改善肌肤痘印的护肤品组合物及制备方法 | |
CN112972323A (zh) | 一种大麻叶精华液及其制备方法 | |
JP2018127407A (ja) | 表皮正常化剤並びにこれを含有する外用剤及び化粧料 | |
CN113244148A (zh) | 一种护肤组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221216 |
|
RJ01 | Rejection of invention patent application after publication |